Viant Technology Inc. Form 8-K Summary
Business Context and Reporting Period
Viant Technology Inc. filed a Form 8-K dated June 4, 2024, with the report signed on June 10, 2024. The filing reports results of the June 4, 2024 annual meeting, a director resignation effective June 5, 2024, and subsequent Nasdaq notification received June 7, 2024.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.
Material Changes and Corporate Governance
- Elizabeth Williams resigned from the Board and Audit Committee effective June 5, 2024, following her appointment as Chief Executive Officer of El Pollo Loco Holdings, Inc.
- The company stated that Ms. Williams’s resignation was not due to any disagreement with the company’s operations, policies, or practices.
- Her resignation left the Audit Committee with two directors, resulting in non-compliance with Nasdaq Listing Rule 5605(c)(2), which generally requires at least three independent Audit Committee directors.
- Nasdaq granted the applicable cure period, expiring at the earlier of the expected June 2025 annual meeting or June 5, 2025. The company intends to appoint an additional independent director before the deadline.
- Stockholders elected Tim Vanderhook and Vivian Yang as Class III directors, each serving until the 2027 annual meeting or until a successor is elected and qualified.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Annual Meeting Voting Results
Approximately 91.3% of the voting power was represented at the annual meeting. As of the April 11, 2024 record date, 16,499,599 Class A shares and 46,984,825 Class B shares were outstanding and entitled to vote; each share carried one vote.
| Proposal | Results |
|---|---|
| Tim Vanderhook, Class III director | 50,198,724 for; 2,416,507 withheld; 5,368,874 broker non-votes |
| Vivian Yang, Class III director | 50,392,653 for; 2,222,578 withheld; 5,368,874 broker non-votes |
| Ratification of Deloitte & Touche LLP | 57,734,832 for; 241,980 against; 7,293 abstentions; no broker non-votes |
Outlook, Risks, and Unusual Items
- The principal forward-looking statement concerns the company’s plan to regain Nasdaq compliance by adding an independent director to the Board and Audit Committee.
- Failure to appoint a qualifying director within the cure period could result in further Nasdaq listing consequences.
- The company referenced general political, economic, competitive, market, regulatory, and business risks, along with risk factors in its 2023 Form 10-K and March 31, 2024 Form 10-Q.
- No earnings guidance, financial outlook, liquidity contingency, debt modification, or other financial unusual item was disclosed.
Key Facts for Investors to Verify
- Whether Viant appoints an additional independent director and restores compliance before the earlier of the 2025 annual meeting and June 5, 2025.
- Whether the Audit Committee satisfies Nasdaq’s independence and composition requirements after the appointment.
- The impact, if any, of the director transition on governance, committee oversight, and future filings.
- The company’s subsequent financial results and guidance, which are not addressed in this Form 8-K.